人血白蛋白在肝硬化及其并发症中的应用

李雅欣; 丁惠国

doi:10.12449/JCH250303

人血白蛋白在肝硬化及其并发症中的应用

DOI: 10.12449/JCH250303

李雅欣,
丁惠国^, ,

首都医科大学附属北京佑安医院肝病消化中心，北京 100069

基金项目:

首都卫生发展科研专项 (2022-1-2181)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：李雅欣负责查找文献，撰写文稿；丁惠国负责确定写作思路，指导文章撰写及最终定稿。

详细信息

通信作者:
丁惠国， dinghuiguo@ccmu.edu.cn （ORCID： 0000-0002-8716-4926）

计量
- 文章访问数: 1561
- HTML全文浏览量: 96
- PDF下载量: 70
- 被引次数: 0
出版历程
- 收稿日期: 2024-10-08
- 录用日期: 2025-01-15
- 出版日期: 2025-03-25

The application of human serum albumin in liver cirrhosis and its complications

Yaxin LI,
Huiguo DING^{,
,}

Department of Hepatology and Gastroenterology，Beijing YouAn Hospital，Capital Medical University，Beijing 100069，China

Research funding:

Capital Medical Development and Research Fund (2022-1-2181)

More Information

Corresponding author: DING Huiguo， dinghuiguo@ccmu.edu.cn （ORCID： 0000-0002-8716-4926）

摘要

摘要: 白蛋白由肝脏生物合成，当肝脏严重损伤时，白蛋白不仅合成减少，其结构亦发生变化（如甲基化、糖基化等增多），导致循环中有效白蛋白浓度显著降低。白蛋白不仅能维持血浆胶体渗透压，还具备抗氧化、抗炎、免疫调节和物质运输等非胶体功能。目前，指南推荐人血白蛋白短期用于肝硬化患者大量放腹水、肝肾综合征和自发性细菌性腹膜炎的治疗，可降低病死率；人血白蛋白在肝硬化低钠血症、非自发性细菌性腹膜炎感染和肝性脑病中可能改善预后。但是，人血白蛋白在肝硬化及相关并发症中应用的剂量及长期应用的效果仍存在争议。
- 白蛋白类 /
- 肝硬化 /
- 腹水 /
- 肝肾综合征 /
- 肝性脑病 /
- 治疗学
Abstract: Albumin is synthesized in the liver， and in case of severe liver injury， albumin synthesis is reduced with structural alterations （such as an increase in methylation and glycosylation）， leading to a significant reduction in effective albumin in circulation. Albumin not only maintains plasma oncotic pressure， but also has the functions of antioxidation， anti-inflammation， immunomodulation， and transport. Current guidelines recommend the short-term application of human serum albumin in the treatment of large-volume paracentesis， hepatorenal syndrome， and spontaneous bacterial peritonitis in patients with liver cirrhosis， as it is shown that human serum albumin can help to reduce mortality. In addition， human serum albumin may improve the prognosis of cirrhotic patients with hyponatremia， non-SBP infections， and hepatic encephalopathy. However， there are still controversies over the application of human serum albumin in liver cirrhosis and related complications in terms of optimal dose and long-term efficacy.
- Albumins /
- Liver Cirrhosis /
- Ascites /
- Hepatorenal Syndrome /
- Hepatic Encephalopathy /
- Therapeutics

HTML全文

表 1 人血白蛋白在肝硬化失代偿期各种并发症、脓毒症治疗相关临床研究结果的总结

Table 1. Summary of clinical research results on human serum albumin for treating various complications in decompensated cirrhosis and sepsis

研究名称	研究对象	白蛋白组 vs 对照组	主要研究结果	结论
ALBIOS 2014年^［43］	严重脓毒症和脓毒性休克患者	20%白蛋白 vs 晶体液	改善血流动力学，但未降低病死率	表明具有稳定血流动力学的潜力
SAFE 2004年^［44］	重症患者（包括脓毒症患者）	4%白蛋白 vs 0.9%生理盐水	两组病死率相似，白蛋白治疗在脓毒症亚组存在获益	可能为脓毒症患者提供获益
EARSS 2011年^［45］	脓毒性休克患者	大剂量白蛋白（60 g/d） vs 0.9%生理盐水	对病死率和器官衰竭无改善	提高生存率的效果有限
FRISC 2021年^［46］	肝硬化合并脓毒症导致的低血压患者	5%白蛋白 vs 0.9%生理盐水	改善低血压，提高短期生存率	在肝硬化合并脓毒症患者中有效
ALPS 2022年^［38］	肝硬化合并脓毒症导致的低血压患者	20%白蛋白（0.5～1.0 g/kg） vs 晶体液	可有效达到目标平均动脉压，减少透析次数	推荐用于肝硬化合并脓毒症患者
ATTIRE 2021年^［34］	肝硬化合并低白蛋白血症住院患者	20%白蛋白14天，维持血清白蛋白30 g/L vs 标准治疗	对3天、15天和出院时感染、肾功能不全及病死率无改善，对6个月病死率无改善	质疑大剂量白蛋白在肝硬化患者中的疗效
RASP 2019年^［47］	合并脓毒症的癌症患者	4%白蛋白 vs 乳酸林格氏液	两组7天、28天病死率无差异	对癌症患者合并脓毒症治疗无效
ANSWER 2018年^［41］	肝硬化单纯性腹水患者	标准治疗联合人血白蛋白（40 g/次，每周2次，共2周；后40 g每周1次） 18个月 vs 标准治疗	血清白蛋白水平明显增加，难治性腹水、感染、HRS和HE发生率显著下降，病死率降低	肝硬化腹水患者长期应用提高生存率
荟萃分析 2023年^［48］	脓毒症和脓毒性休克患者	各种浓度白蛋白 vs 晶体液	20%白蛋白降低了脓毒性休克患者的90天病死率	存在潜在获益，需进一步研究

下载: 导出CSV

参考文献(51)

[1]	GINÈS P, KRAG A, ABRALDES JG, et al. Liver cirrhosis[J]. Lancet, 2021, 398( 10308): 1359- 1376. DOI: 10.1016/s0140-6736(21)01374-x.
[2]	de MATTOS ÂZ, SIMONETTO DA, TERRA C, et al. Albumin administration in patients with cirrhosis: Current role and novel perspectives[J]. World J Gastroenterol, 2022, 28( 33): 4773- 4786. DOI: 10.3748/wjg.v28.i33.4773.
[3]	POMPILI E, ZACCHERINI G, BALDASSARRE M, et al. Albumin administration in internal medicine: A journey between effectiveness and futility[J]. Eur J Intern Med, 2023, 117: 28- 37. DOI: 10.1016/j.ejim.2023.07.003.
[4]	BAI ZH, MÉNDEZ-SÁNCHEZ N, ROMEIRO FG, et al. Use of albumin infusion for cirrhosis-related complications: An international position statement[J]. JHEP Rep, 2023, 5( 8): 100785. DOI: 10.1016/j.jhepr.2023.100785.
[5]	ANDERSEN JT, DALHUS B, VIUFF D, et al. Extending serum half-life of albumin by engineering neonatal Fc receptor(FcRn) binding[J]. J Biol Chem, 2014, 289( 19): 13492- 13502. DOI: 10.1074/jbc.M114.549832.
[6]	WU NJ, LIU TT, TIAN MM, et al. Albumin, an interesting and functionally diverse protein, varies from‘native’ to‘effective’(Review)[J]. Mol Med Rep, 2024, 29( 2): 24. DOI: 10.3892/mmr.2023.13147.
[7]	GARCIA-MARTINEZ R, CARACENI P, BERNARDI M, et al. Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications[J]. Hepatology, 2013, 58( 5): 1836- 1846. DOI: 10.1002/hep.26338.
[8]	CASULLERAS M, FLORES-COSTA R, DURAN-GÜELL M, et al. Albumin lipidomics reveals meaningful compositional changes in advanced cirrhosis and its potential to promote inflammation resolution[J]. Hepatol Commun, 2022, 6( 6): 1443- 1456. DOI: 10.1002/hep4.1893.
[9]	CASULLERAS M, FLORES-COSTA R, DURAN-GÜELL M, et al. Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis[J]. Sci Transl Med, 2020, 12( 566): eaax5135. DOI: 10.1126/scitranslmed.aax5135.
[10]	BERNARDI M, ANGELI P, CLARIA J, et al. Albumin in decompensated cirrhosis: New concepts and perspectives[J]. Gut, 2020, 69( 6): 1127- 1138. DOI: 10.1136/gutjnl-2019-318843.
[11]	AITHAL GP, PALANIYAPPAN N, CHINA L, et al. Guidelines on the management of ascites in cirrhosis[J]. Gut, 2021, 70( 1): 9- 29. DOI: 10.1136/gutjnl-2020-321790.
[12]	SIMONETTI RG, PERRICONE G, NIKOLOVA D, et al. Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis[J]. Cochrane Database Syst Rev, 2019, 6( 6): CD004039. DOI: 10.1002/14651858.CD004039.pub2.
[13]	SHRESTHA DB, BUDHATHOKI P, SEDHAI YR, et al. Safety and efficacy of human serum albumin treatment in patients with cirrhotic ascites undergoing paracentesis: A systematic review and meta-analysis[J]. Ann Hepatol, 2021, 26: 100547. DOI: 10.1016/j.aohep.2021.100547.
[14]	BAI ZH, WANG L, WANG R, et al. Use of human albumin infusion in cirrhotic patients: A systematic review and meta-analysis of randomized controlled trials[J]. Hepatol Int, 2022, 16( 6): 1468- 1483. DOI: 10.1007/s12072-022-10374-z.
[15]	XU XY, DING HG, JIA JD, et al. Chinese guidelines on the management of ascites in cirrhosis: Chinese Society of Hepatology, Chinese Medical Association[J]. Hepatol Int, 2024, 18( 4): 1071- 1089. DOI: 10.1007/s12072-024-10697-z.
[16]	ALESSANDRIA C, ELIA C, MEZZABOTTA L, et al. Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: Standard vs half albumin doses. A prospective, randomized, unblinded pilot study[J]. Dig Liver Dis, 2011, 43( 11): 881- 886. DOI: 10.1016/j.dld.2011.06.001.
[17]	CHINA L, FREEMANTLE N, FORREST E, et al. A randomized trial of albumin infusions in hospitalized patients with cirrhosis[J]. N Engl J Med, 2021, 384( 9): 808- 817. DOI: 10.1056/NEJMoa2022166.
[18]	ARORA V, VIJAYARAGHAVAN R, MAIWALL R, et al. Paracentesis-induced circulatory dysfunction with modest-volume paracentesis is partly ameliorated by albumin infusion in acute-on-chronic liver failure[J]. Hepatology, 2020, 72( 3): 1043- 1055. DOI: 10.1002/hep.31071.
[19]	TORP N, ISRAELSEN M, COENRAAD M, et al. Personalised human albumin in patients with cirrhosis and ascites: Design and rationale for the ALB-TRIAL—a randomised clinical biomarker validation trial[J]. BMJ Open, 2024, 14( 2): e079309. DOI: 10.1136/bmjopen-2023-079309.
[20]	MATTOS AA, WILTGEN D, JOTZ RF, et al. Spontaneous bacterial peritonitis and extraperitoneal infections in patients with cirrhosis[J]. Ann Hepatol, 2020, 19( 5): 451- 457. DOI: 10.1016/j.aohep.2020.04.010.
[21]	PAINE CH, BIGGINS SW, PICHLER RH. Albumin in cirrhosis: More than a colloid[J]. Curr Treat Options Gastroenterol, 2019, 17( 2): 231- 243. DOI: 10.1007/s11938-019-00227-4.
[22]	SORT P, NAVASA M, ARROYO V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis[J]. N Engl J Med, 1999, 341( 6): 403- 409. DOI: 10.1056/NEJM199908053410603.
[23]	KAR PS, VENISHETTY S, LAROIA ST, et al. Tolerance of standard dose albumin infused over 6 hrs for treatment of spontaneous bacterial peritonitis-a randomized controlled trial[J]. Indian J Gastroenterol, 2023, 42( 4): 505- 516. DOI: 10.1007/s12664-023-01389-x.
[24]	GARCIA-TSAO G, ABRALDES JG, RICH NE, et al. AGA clinical practice update on the use of vasoactive drugs and intravenous albumin in cirrhosis: Expert review[J]. Gastroenterology, 2024, 166( 1): 202- 210. DOI: 10.1053/j.gastro.2023.10.016.
[25]	NADIM MK, KELLUM JA, FORNI L, et al. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative(ADQI) and International Club of Ascites(ICA) joint multidisciplinary consensus meeting[J]. J Hepatol, 2024, 81( 1): 163- 183. DOI: 10.1016/j.jhep.2024.03.031.
[26]	ORTEGA R, GINÈS P, URIZ J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study[J]. Hepatology, 2002, 36( 4 Pt 1): 941- 948. DOI: 10.1053/jhep.2002.35819.
[27]	BAI ZH, GUO XZ, TACKE F, et al. Association of serum albumin level with incidence and mortality of overt hepatic encephalopathy in cirrhosis during hospitalization[J]. Therap Adv Gastroenterol, 2019, 12: 1756284819881302. DOI: 10.1177/1756284819881302.
[28]	IS B, BOMBASSARO IZ, TOVO CV, et al. Albumin in the management of hepatic encephalopathy: A systematic review and meta-analysis[J]. Ann Hepatol, 2021, 26: 100541. DOI: 10.1016/j.aohep.2021.100541.
[29]	TEH KB, LOO JH, TAM YC, et al. Efficacy and safety of albumin infusion for overt hepatic encephalopathy: A systematic review and meta-analysis[J]. Dig Liver Dis, 2021, 53( 7): 817- 823. DOI: 10.1016/j.dld.2021.04.030.
[30]	SHARMA BC, SINGH J, SRIVASTAVA S, et al. Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy[J]. J Gastroenterol Hepatol, 2017, 32( 6): 1234- 1239. DOI: 10.1111/jgh.13666.
[31]	FAGAN A, GAVIS EA, GALLAGHER ML, et al. A double-blind randomized placebo-controlled trial of albumin in outpatients with hepatic encephalopathy: HEAL study[J]. J Hepatol, 2023, 78( 2): 312- 321. DOI: 10.1016/j.jhep.2022.09.009.
[32]	BAJAJ JS, TANDON P, O’LEARY JG, et al. The impact of albumin use on resolution of hyponatremia in hospitalized patients with cirrhosis[J]. Am J Gastroenterol, 2018, 113( 9): 1339. DOI: 10.1038/s41395-018-0119-3.
[33]	BAI ZH, XU WT, CHAI L, et al. Effects of short-term human albumin infusion for the prevention and treatment of hyponatremia in patients with liver cirrhosis[J]. J Clin Med, 2022, 12( 1): 107. DOI: 10.3390/jcm12010107.
[34]	CHINA L, FREEMANTLE N, FORREST E, et al. Targeted albumin therapy does not improve short-term outcome in hyponatremic patients hospitalized with complications of cirrhosis: Data from the ATTIRE trial[J]. Am J Gastroenterol, 2021, 116( 11): 2292- 2295. DOI: 10.14309/ajg.0000000000001488.
[35]	FERNÁNDEZ J, CLÀRIA J, AMORÓS A, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis[J]. Gastroenterology, 2019, 157( 1): 149- 162. DOI: 10.1053/j.gastro.2019.03.021.
[36]	FERNÁNDEZ J, ANGELI P, TREBICKA J, et al. Efficacy of albumin treatment for patients with cirrhosis and infections unrelated to spontaneous bacterial peritonitis[J]. Clin Gastroenterol Hepatol, 2020, 18( 4): 963- 973. e 14. DOI: 10.1016/j.cgh.2019.07.055.
[37]	WONG YJ, QIU TY, TAM YC, et al. Efficacy and Safety of IV albumin for non-spontaneous bacterial peritonitis infection among patients with cirrhosis: A systematic review and meta-analysis[J]. Dig Liver Dis, 2020, 52( 10): 1137- 1142. DOI: 10.1016/j.dld.2020.05.047.
[38]	MAIWALL R, KUMAR A, PASUPULETI SSR, et al. A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension[ALPS trial][J]. J Hepatol, 2022, 77( 3): 670- 682. DOI: 10.1016/j.jhep.2022.03.043.
[39]	CALLUM J, SKUBAS NJ, BATHLA A, et al. Use of intravenous albumin: A guideline from the international collaboration for transfusion medicine guidelines[J]. Chest, 2024, 166( 2): 321- 338. DOI: 10.1016/j.chest.2024.02.049.
[40]	DI PASCOLI M, FASOLATO S, PIANO S, et al. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites[J]. Liver Int, 2019, 39( 1): 98- 105. DOI: 10.1111/liv.13968.
[41]	CARACENI P, RIGGIO O, ANGELI P, et al. Long-term albumin administration in decompensated cirrhosis(ANSWER): An open-label randomised trial[J]. Lancet, 2018, 391( 10138): 2417- 2429. DOI: 10.1016/S0140-6736(18)30840-7.
[42]	WIEDERMANN CJ. Controversies surrounding albumin use in sepsis: Lessons from cirrhosis[J]. Int J Mol Sci, 2023, 24( 24): 17606. DOI: 10.3390/ijms242417606.
[43]	CAIRONI P, TOGNONI G, MASSON S, et al. Albumin replacement in patients with severe sepsis or septic shock[J]. N Engl J Med, 2014, 370( 15): 1412- 1421. DOI: 10.1056/NEJMoa1305727.
[44]	FINFER S, BELLOMO R, BOYCE N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit[J]. N Engl J Med, 2004, 350( 22): 2247- 2256. DOI: 10.1056/NEJMoa040232.
[45]	CHARPENTIER J, MIRA JP. Efficacy and tolerance of hyperoncotic albumin administration in septic shock patients: The EARSS study[J]. Intensive Care Med, 2011, 37: S115.
[46]	PHILIPS CA, MAIWALL R, SHARMA MK, et al. Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis(FRISC study): A randomized controlled trial[J]. Hepatol Int, 2021, 15( 4): 983- 994. DOI: 10.1007/s12072-021-10164-z.
[47]	PARK CHL, DE ALMEIDA JP, DE OLIVEIRA GQ, et al. Lactated Ringer’s versus 4% albumin on lactated Ringer’s in early sepsis therapy in cancer patients: A pilot single-center randomized trial[J]. Crit Care Med, 2019, 47( 10): e798- e805. DOI: 10.1097/CCM.0000000000003900.
[48]	GENG L, TIAN XX, GAO ZF, et al. Different concentrations of albumin versus crystalloid in patients with sepsis and septic shock: A meta-analysis of randomized clinical trials[J]. J Intensive Care Med, 2023, 38( 8): 679- 689. DOI: 10.1177/08850666231170778.
[49]	SHASTHRY SM, KUMAR M, KHUMUCKHAM JS, et al. Changes in cardiac output and incidence of volume overload in cirrhotics receiving 20% albumin infusion[J]. Liver Int, 2017, 37( 8): 1167- 1176. DOI: 10.1111/liv.13375.
[50]	JAGDISH RK, MARAS JS, SARIN SK. Albumin in advanced liver diseases: The good and bad of a drug![J]. Hepatology, 2021, 74( 5): 2848- 2862. DOI: 10.1002/hep.31836.
[51]	FORSTER CM, HALLS S, ALLARAKHIA S, et al. Improving appropriate use of intravenous albumin: Results of a single-centre audit and multifaceted intervention[J]. BMJ Open Qual, 2024, 13( 2): e002534. DOI: 10.1136/bmjoq-2023-002534.